Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.

Cancer research - 16 Jun 2025

Srivastava Jyoti, Yadav Vipin K, Jimenez Rachel V, Phadatare Pravin R, Inamdar Ninad A, Young Montana M, Bacchiocchi Antonella, Halaban Ruth, Fang Bin, Pulido Alvaro de Mingo, Tsai Kenneth Y, Smalley Keiran S M, Koomen John M, Rodriguez Paulo C, Premi Sanjay

Abstract excerpt

Activating NRAS mutations occur in 15% to 25% of all melanomas. However, this subtype remains refractory to existing therapeutics, including immunotherapy and RAS inhibitors; therefore, identifying innovative treatment strategies is of utmost importance. We investigated the role of nitrosylation, a nitric oxide-induced posttranslational modification, in melanoma progression and therapeutic resistance. Inhibiting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Membrane Proteins

Share to Mice, Inbred C57BL

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40287947
DOI: 10.1158/0008-5472.CAN-24-0693
PMCID: PMC12167936

Genes

NRAS
HMGB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant Melanoma to MEK Inhibitors.PMID 40287947Read ↗

Targeting mutant NRAS signaling pathways in melanoma.Semantic proximity Read ↗

Targeting the MAPK pathway for NRAS mutant melanoma: from mechanism to clinic.Semantic proximity Read ↗

A Genome-Wide Screen Identifies PDPK1 as a Target to Enhance the Efficacy of MEK1/2 Inhibitors in NRAS Mutant Melanoma.Semantic proximity Read ↗

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS-mutant melanoma cells: Insights into mode of action and resistance mechanisms.Semantic proximity Read ↗

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.Semantic proximity Read ↗

NRAS mutant melanoma: Towards better therapies.Semantic proximity Read ↗

HSP70 inhibition blocks adaptive resistance and synergizes with MEK inhibition for the treatment of NRAS-mutant melanoma.Semantic proximity Read ↗

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.Semantic proximity Read ↗

Inhibition of p90 ribosomal S6 kinases disrupts melanoma cell growth and immune evasionSemantic proximity Read ↗

MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS -, and NF1 -Mutant MelanomasSemantic proximity Read ↗

Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.Semantic proximity Read ↗

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.